Core--Cell therapy resource

核心--细胞治疗资源

• 批准号: 7055188
• 负责人: Shelly Heimfeld
• 金额: $ 38.15万
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2010-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7055188
• 关键词: biomedical facility; blood banks; blood preservation; cord blood; cryopreservation; dogs; flow cytometry; human subject; radiation dosage; tissue donors

The primary functions of Cell Therapy Core are to assist Projects 2-6 by making available critical equipment and technical expertise covering three distinct aspects of research support: optimal cryopreservation and storage of canine and human cells; characterization of canine transplantation products by flow cytometry; and stem cell enrichment from canine components. Specifically, this Core will: (A) store peripheral blood and/or serum specimens obtained from dogs and humans exposed to varying doses of irradiation as part of biodosimetry development Projects 2 and 3, and create a canine cord blood bank in support of Project 5. (B) Enrich for canine CD34+ cells to be used as the starting material for the ex vivo expanded myeloid progenitor cell studies described in Projects 4 and 5. As part of these projects the development of more optimized cryopreservation and storage conditions for these types of cells will also be necessary. (C) Analyze by flow cytometry all the various canine components used for transplantation as part of Projects 4-6. This proposed Cell Therapy Core represents an enhancement of an already existing Cell Processing resource that has considerable expertise in each of these areas. The existing resource manages several Research and Clinical Cell Repositories that contain a variety of cell types, encompassing over 50,000 different specimens stored in the vapor phase of liquid nitrogen freezers, including components used to support human therapeutic studies. The Processing Core has performed over 30 canine CD34+ cell enrichments, achieving excellent purities of >80% and yields of 50%. Finally, the Core specializes in flow cytometry analysis, and has established a database with over 3500 human clinical transplant components characterized for the content of hematopoietic stem cells (CD34), T-cell subsets (CDS, CD4, CDS, CD45RA), dendritic cells (CD14, BDCA-2), B-cells (CD19, CD22) and NK cell (CD56) subsets. These data form the basis for important correlative studies to investigate associations of these cell types with several clinical outcomes. In summary, Cell Therapy Core D will provide unique and critical services in support of Projects 2-6 described in this grant application, specifically optimal cryopreservation and storage, cell selection, and flow cytometry analysis, and will be able to provide those services in a more efficient and cost-effective manner.

细胞治疗核心的主要功能是通过提供关键设备和技术专业知识来协助项目 2-6，涵盖研究支持的三个不同方面：犬和人类细胞的最佳冷冻保存和储存；通过流式细胞术表征犬移植产品；以及从犬科动物成分中富集干细胞。具体来说，该核心将：（A）作为生物剂量测定开发项目 2 和 3 的一部分，存储从暴露于不同剂量辐射的狗和人类身上获得的外周血和/或血清样本，并创建一个犬脐带血库以支持项目 5 (B) 富集犬 CD34+ 细胞，用作离体扩增骨髓的起始材料。 项目 4 和项目 5 中描述的祖细胞研究。作为这些项目的一部分，还需要为这些类型的细胞开发更优化的冷冻保存和储存条件。 (C) 作为项目 4-6 的一部分，通过流式细胞术分析用于移植的所有各种犬科动物成分。拟议的细胞治疗核心代表了对现有细胞处理资源的增强，该资源在每个领域都拥有丰富的专业知识。现有资源管理着多个研究和临床细胞存储库，其中包含各种细胞类型，包括存储在液氮冷冻机气相中的 50,000 多个不同样本，包括用于支持人类治疗研究的组件。处理核心已执行超过 30 种犬 CD34+ 细胞 富集，实现 >80% 的优异纯度和 50% 的收率。最后，核心专门从事流式细胞术分析，并建立了包含超过3500个人类临床移植成分的数据库，其特征在于造血干细胞（CD34）、T细胞亚群（CDS、CD4、CDS、CD45RA）、树突状细胞的含量（CD14、BDCA-2）、B 细胞（CD19、CD22）和 NK 细胞（CD56）亚群。这些数据构成了重要相关研究的基础，以调查这些细胞类型与多种临床结果的关联。总之，细胞治疗核心 D 将提供独特且关键的服务来支持本拨款申请中描述的项目 2-6，特别是最佳冷冻保存和储存、细胞选择和 流式细胞术分析，并将能够以更高效和更具成本效益的方式提供这些服务。